• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Galecto, Inc.

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
March 09, 2023
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
March 02, 2023
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto to Participate in SVB Securities Global Biopharma Conference
February 01, 2023
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
December 07, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto Reports Third Quarter Operating and Financial Results
November 08, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
November 08, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto to Participate in Jefferies London Healthcare Conference
November 03, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
October 31, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute
October 19, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap